## What is the pathway?

This pathway supports primary care providers and clinical pharmacists in caring for patients with diabetes and kidney and/or heart disease. This evidence-based pathway is for use in stable ambulatory patients over 18 years of age. It supports guideline concordant cardio-renal protective therapies that promote the use of sodium/glucose cotransporter-2 inhibitors (SGLT2is) in persons with diabetic kidney disease. The pathway addresses cardiovascular, endocrinology and kidney treatment in a community setting.



## Why is the pathway needed?

Evidence from large high-quality randomized control trials supports SGLT2i use beyond glucose control in diabetes. SGLT2i use can reduce the risk of kidney disease progression, hospitalization for heart failure and major adverse cardiovascular events in adults with diabetes and Chronic Kidney Disease (CKD) (Guidelines from Kidney Disease Improving Global Outcomes and Diabetes Canada). However, the use of SGLT2is in people with CKD (eGFR>30) and diabetes was found to be low at 26.7% in a 2018-2019 Alberta cohort. This pathway is intended to support care of patients with diabetes and kidney and/or heart disease, especially by increasing the use of SGLT2is in this population.

## **Current Status and Next Steps**

A multidisciplinary working group has developed, tested, revised, and finalized this provincial decision support pathway for use by primary care providers and pharmacists. The pathway is posted to the Alberta Provincial Pathways site and can be found by scanning the QR code above or directly at: <u>Provincial Chronic Kidney Disease in Diabetes Mellitus 2 (CKD in DM2) Primary Care [Team] Pathway for</u> <u>Optimizing Kidney and Cardiovascular Outcomes (albertahealthservices.ca)</u>

We are in the process of disseminating the algorithm as well as developing a series of strategies to encourage the uptake of SGLT2 is in appropriate persons and to evaluate the impact of our efforts.

For more information, contact the Kidney Health Section, Medicine SCN at medicinescn@ahs.ca.

